{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:43:26Z","timestamp":1794375806076,"version":"4.9.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Seasonal allergic conjunctivitis (SAC) is a hypersensitivity condition characterized by itching, tearing, and redness. It affects over 20% of the general population with limited therapeutic options. Reproxalap, a novel small-molecule aldehyde trap, has emerged as a potential treatment option for SAC by targeting reactive aldehydes involved in inflammation. In this systematic review and meta-analysis, we assessed the efficacy and safety of Reproxalap in treating SAC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Multiple databases were searched including PubMed, Cochrane Library, Scopus, and Google Scholar, to identify relevant studies. Clinical trials involving patients diagnosed with SAC and treated with Reproxalap (0.25% or 0.5%) were included. The primary outcomes were symptom relief (efficacy) and side effects (safety). Data extraction and risk of bias assessment were performed independently by two reviewers. Meta-analysis was conducted using RevMan 5.4 software.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Five RCTs involving 625 participants were included. Reproxalap significantly reduced ocular itching compared to control groups for both 0.25% (SMD: -0.31, 95% CI: -0.50 to -0.13, <jats:italic>P<\/jats:italic>\u2009=\u2009.001) and 0.5% concentrations (SMD: -0.31, 95% CI: -0.51 to -0.10, <jats:italic>P<\/jats:italic>\u2009=\u20090.004). No significant difference was observed between the two doses (SMD: -0.02, 95% CI: -0.23 to 0.19, <jats:italic>P<\/jats:italic>\u2009=\u20090.83). Side effects were more frequent in both Reproxalap groups compared to controls, with odds ratios of 35.31 (95% CI: 17.83 to 69.90, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.00001) for 0.25% and 45.64 (95% CI: 18.49 to 112.66, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.00001) for 0.5%. The 0.5% dose had significantly higher odds of side effects compared to the 0.25% dose (OR: 1.66, 95% CI: 1.10 to 2.51, <jats:italic>P<\/jats:italic>\u2009=\u20090.02). Heterogeneity was low for all outcomes (I<jats:sup>2<\/jats:sup>\u2009=\u20090%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Reproxalap reduces ocular itching associated with SAC. While both 0.25% and 0.5% concentrations are effective, safe and tolerable. Further research should focus on the long-term benefits and applicability of Reproxalap on diverse populations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12348-025-00497-3","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T18:03:48Z","timestamp":1745863428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Reproxalap in patients with seasonal allergic conjunctivitis: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"15","author":[{"given":"Ammar","family":"Elgadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malaz M.","family":"Abdalmotalib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibyan","family":"Noorallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbal","family":"Abdelazim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Ali Merghani","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"497_CR1","doi-asserted-by":"publisher","unstructured":"Bielory BP, O\u2019Brien TP, Bielory L. Management of seasonal allergic conjunctivitis: guide to therapy. Acta Ophthalmologica . 2012;90(5):399\u2013407. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1111\/j.1755-3768.2011.02272.x. Cited 2024 Nov 9","DOI":"10.1111\/j.1755-3768.2011.02272.x"},{"key":"497_CR2","doi-asserted-by":"crossref","unstructured":"Ono SJ, Abelson MB. Allergic conjunctivitis: Update on pathophysiology and prospects for future treatment. Journal of Allergy and Clinical Immunology. 2005;115(1):118\u201322. Available from: https:\/\/www.jacionline.org\/article\/S0091-6749(04)03032-5\/fulltext. Cited 2024 Nov 9","DOI":"10.1016\/j.jaci.2004.10.042"},{"issue":"2","key":"497_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2500\/aap.2012.33.3525","volume":"33","author":"L Bielory","year":"2012","unstructured":"Bielory L (2012) Allergic conjunctivitis: the evolution of therapeutic options. Allergy Asthma Proc 33(2):129\u2013139","journal-title":"Allergy Asthma Proc"},{"key":"497_CR4","unstructured":"Baab S, Le PH, Gurnani B, Kinzer EE. Allergic Conjunctivitis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK448118\/. Cited 2024 Oct 31"},{"issue":"1","key":"497_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1076\/opep.11.1.17.26437","volume":"11","author":"AD Pitt","year":"2004","unstructured":"Pitt AD, Smith AF, Lindsell L, Voon LW, Rose PW, Bron AJ (2004) Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 11(1):17\u201333","journal-title":"Ophthalmic Epidemiol"},{"key":"497_CR6","doi-asserted-by":"publisher","unstructured":"Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Eyes and Vision Group, editor. Cochrane Database of Systematic Reviews. 2015;2015(6). Available from: http:\/\/doi.wiley.com\/https:\/\/doi.org\/10.1002\/14651858.CD009566.pub2. Cited 2024 Oct 31","DOI":"10.1002\/14651858.CD009566.pub2"},{"key":"497_CR7","doi-asserted-by":"crossref","unstructured":"Tariq F. Allergic Conjunctivitis: Review of Current Types, Treatments, and Trends. Life. 2024;14(6):650. Available from: https:\/\/www.mdpi.com\/2075-1729\/14\/6\/650. Cited 2024 Oct 31","DOI":"10.3390\/life14060650"},{"key":"497_CR8","doi-asserted-by":"crossref","unstructured":"Holland EJ, Fingeret M, Mah FS. Use of Topical Steroids in Conjunctivitis: A Review of the Evidence. Cornea. 2019;38(8):1062. Available from: https:\/\/journals.lww.com\/corneajrnl\/fulltext\/2019\/08000\/use_of_topical_steroids_in_conjunctivitis__a.26.aspx. Cited 2024 Oct 31","DOI":"10.1097\/ICO.0000000000001982"},{"key":"497_CR9","unstructured":"Feroze KB, Zeppieri M, Khazaeni L. Steroid-Induced Glaucoma. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 . Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430903\/. Cited 2024 Oct 31"},{"key":"497_CR10","doi-asserted-by":"crossref","unstructured":"Starr CE, Nichols KK, Lang JR, Brady TC. The Phase 3 INVIGORATE Trial of Reproxalap in Patients with Seasonal Allergic Conjunctivitis. OPTH. 2023;17:3867\u201375. Available from: https:\/\/www.dovepress.com\/the-phase-3-invigorate-trial-of-reproxalap-in-patients-with-seasonal-a-peer-reviewed-fulltext-article-OPTH. Cited 2024 Oct 31","DOI":"10.2147\/OPTH.S441009"},{"key":"497_CR11","unstructured":"Reproxalap ophthalmic dosing, indications, interactions, adverse effects, and more. Available from: https:\/\/reference.medscape.com\/drug\/reproxalap-ophthalmic-4000363. Cited 2024 Oct 31"},{"key":"497_CR12","doi-asserted-by":"crossref","unstructured":"Qu J, Li Y, Zhong W, Gao P, Hu C. Recent developments in the role of reactive oxygen species in allergic asthma. Journal of Thoracic Disease. 2017;9(1):E32. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5303105\/. Cited 2024 Oct 31","DOI":"10.21037\/jtd.2017.01.05"},{"key":"497_CR13","doi-asserted-by":"crossref","unstructured":"Zhuang D, Misra SL, Mugisho OO, Rupenthal ID, Craig JP. NLRP3 Inflammasome as a Potential Therapeutic Target in Dry Eye Disease. International Journal of Molecular Sciences. 2023;24(13):10866. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10341612\/. Cited 2024 Oct 31","DOI":"10.3390\/ijms241310866"},{"key":"497_CR14","doi-asserted-by":"publisher","unstructured":"Mahmoud AM, Wilkinson FL, Sandhu MA, Lightfoot AP. The Interplay of Oxidative Stress and Inflammation: Mechanistic Insights and Therapeutic Potential of Antioxidants. Oxidative Medicine and Cellular Longevity. 2021;2021(1):9851914. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1155\/2021\/9851914. Cited 2024 Oct 31","DOI":"10.1155\/2021\/9851914"},{"key":"497_CR15","doi-asserted-by":"crossref","unstructured":"Cavanagh B, Gomes PJ, Starr CE, Nichols KK, Brady TC. Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial. Ophthalmology and Therapy. 2022 May 18 [cited 2024 Oct 31];11(4):1449. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9253207\/","DOI":"10.1007\/s40123-022-00520-z"},{"key":"497_CR16","doi-asserted-by":"crossref","unstructured":"Swartz TS, Powell W. Reproxalap for the Treatment of Dry Eye Disease. 2023. Available from: https:\/\/www.touchophthalmology.com\/ocular-surface-disease\/journal-articles\/reproxalap-for-the-treatment-of-dry-eye-disease\/. Cited 2024 Oct 31","DOI":"10.17925\/USOR.2023.17.1.31"},{"key":"497_CR17","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. Available from: https:\/\/www.bmj.com\/content\/366\/bmj.l4898. Cited 2024 Oct 31","DOI":"10.1136\/bmj.l4898"},{"key":"497_CR18","doi-asserted-by":"crossref","unstructured":"Clark D, Karpecki P, Salapatek AM, Sheppard JD, Brady TC. <p>Reproxalap Improves Signs and Symptoms of Allergic Conjunctivitis in an Allergen Chamber: A Real-World Model of Allergen Exposure<\/p>. OPTH. 2022;16:15\u201323. Available from: https:\/\/www.dovepress.com\/reproxalap-improves-signs-and-symptoms-of-allergic-conjunctivitis-in-a-peer-reviewed-fulltext-article-OPTH. Cited 2024 Jul 26","DOI":"10.2147\/OPTH.S345324"},{"key":"497_CR19","doi-asserted-by":"crossref","unstructured":"Clark D, Cavanagh B, Shields AL, Karpecki P, Sheppard J, Brady TC. Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial. American Journal of Ophthalmology. 2021;230:60\u20137. Available from: https:\/\/www.ajo.com\/article\/S0002-9394(21)00222-1\/fulltext. Cited 2024 Jul 26","DOI":"10.1016\/j.ajo.2021.04.023"},{"key":"497_CR20","doi-asserted-by":"publisher","unstructured":"Higdon A, Diers AR, Oh JY, Landar A, Darley-Usmar VM. Cell signalling by reactive lipid species: new concepts and molecular mechanisms. Biochemical Journal. 2012;442(3):453\u201364. Available from: https:\/\/doi.org\/10.1042\/BJ20111752. Cited 2024 Oct 31","DOI":"10.1042\/BJ20111752"},{"key":"497_CR21","doi-asserted-by":"crossref","unstructured":"Rosa ML, Lionetti E, Reibaldi M, Russo A, Longo A, Leonardi S, et al. Allergic conjunctivitis: a comprehensive review of the literature. Italian Journal of Pediatrics . 2013;39:18. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3640929\/. Cited 2024 Oct 31","DOI":"10.1186\/1824-7288-39-18"},{"key":"497_CR22","doi-asserted-by":"crossref","unstructured":"Chigbu DI, Karbach NJ, Abu SL, Hehar NK. Cytokines in Allergic Conjunctivitis: Unraveling Their Pathophysiological Roles. Life. 2024;14(3):350. Available from: https:\/\/www.mdpi.com\/2075-1729\/14\/3\/350. Cited 2024 Oct 31","DOI":"10.3390\/life14030350"},{"key":"497_CR23","doi-asserted-by":"crossref","unstructured":"Kumar K, Qureshi A, Havelikar U, Tiwari A, Patel A. A review on common hazards of steroids use in hypertension. International Journal of Current Pharmaceutical Research. 2023;17\u201322. Available from: https:\/\/journals.innovareacademics.in\/index.php\/ijcpr\/article\/view\/49389. Cited 2024 Oct 31","DOI":"10.22159\/ijcpr.2023v15i5.3052"},{"key":"497_CR24","doi-asserted-by":"publisher","unstructured":"Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara\u2010Blanco A. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database of Systematic Reviews. 2015;(6). Available from: https:\/\/www.cochranelibrary.com\/cdsr\/doi\/https:\/\/doi.org\/10.1002\/14651858.CD009566.pub2\/full. Cited 2024 Dec 20","DOI":"10.1002\/14651858.CD009566.pub2\/full"},{"key":"497_CR25","doi-asserted-by":"publisher","unstructured":"Kandarakis SA, Petrou P, Papakonstantinou E, Spiropoulos D, Rapanou A, Georgalas I. Ocular nonsteroidal inflammatory drugs: where do we stand today? Cutaneous and Ocular Toxicology. 2020;39(3):200\u201312. Available from: https:\/\/doi.org\/10.1080\/15569527.2020.1760876. Cited 2024 Oct 31","DOI":"10.1080\/15569527.2020.1760876"},{"key":"497_CR26","doi-asserted-by":"publisher","unstructured":"Mantelli F, Calder VL, Bonini S. The Anti-Inflammatory Effects of Therapies for Ocular Allergy. Journal of Ocular Pharmacology and Therapeutics. 2013 Nov [cited 2024 Oct 31];29(9):786\u201393. Available from: https:\/\/www.liebertpub.com\/doi\/https:\/\/doi.org\/10.1089\/jop.2013.0161","DOI":"10.1089\/jop.2013.0161"},{"key":"497_CR27","doi-asserted-by":"publisher","unstructured":"Mandell KJ, Clark D, Chu DS, Foster CS, Sheppard J, Brady TC. Randomized Phase 2 Trial of Reproxalap, a Novel Reactive Aldehyde Species Inhibitor, in Patients with Noninfectious Anterior Uveitis: Model for Corticosteroid Replacement. Journal of Ocular Pharmacology and Therapeutics. 2020;36(10):732\u20139. Available from: https:\/\/www.liebertpub.com\/doi\/full\/https:\/\/doi.org\/10.1089\/jop.2020.0056. Cited 2024 Jul 19","DOI":"10.1089\/jop.2020.0056"},{"key":"497_CR28","doi-asserted-by":"crossref","unstructured":"McMullin D, Clark D, Cavanagh B, Karpecki P, Brady TC. <p>A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease<\/p>. OPTH. 2021;15:3889\u2013900. Available from: https:\/\/www.dovepress.com\/a-post-acute-ocular-tolerability-comparison-of-topical-reproxalap-025--peer-reviewed-fulltext-article-OPTH. Cited 2024 Jul 19","DOI":"10.2147\/OPTH.S327691"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-025-00497-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-025-00497-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-025-00497-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T18:03:54Z","timestamp":1745863434000},"score":1,"resource":{"primary":{"URL":"https:\/\/joii-journal.springeropen.com\/articles\/10.1186\/s12348-025-00497-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["497"],"URL":"https:\/\/doi.org\/10.1186\/s12348-025-00497-3","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was waived as this was a secondary analysis of online data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}